Detailed price information for Theravance Bio Ord (TBPH-Q) from The Globe and Mail including charting and trades.

Abstract: As a promising technology in the B5G and 6 G era, integrated sensing and communication (ISAC) can simultaneously support high-quality sensing and communication, and there is a growing ...

Alterity Therapeutics has appointed internationally recognised expert in neurodegenerative diseases Daniel O Claassen as chief medical advisor. ... Read More The post Alterity bolsters clinical ...

Dr. Laroy Borchert passed away on May 1, 2025, at the age of 68 in Tomball, TX. His courage and determination for life were present through the end of his struggle with Multiple Systems Atrophy, an ...

Another phase III failure of Theravance Biopharma Inc.’s norepinephrine reuptake inhibitor ampreloxetine to treat symptomatic neurogenic orthostatic hypotension, this time in patients with the rare ...

Theravance Biopharma shares tumble after Phase 3 trial fails, company halts drug program and explores sale options ahead of earnings.

Theravance Biopharma said on Tuesday its board is reviewing strategic alternatives, including a ​possible sale, after scrapping development of an experimental drug for ‌a rare disorder, sending its ...

In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its ...

Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...

A new study by the University of Turku and Turku University Hospital, Finland, found that a significant proportion of Parkinson's disease diagnoses are later corrected. Up to one in six diagnoses ...

Add Yahoo as a preferred source to see more of our stories on Google. Multiple systems will bring the West beneficial rain and mountain snow. The first round moves in Wednesday into Thursday, but that ...